

## Press release

### **AA139, Adenium's clinical product candidate against multi-drug resistant Gram-negative bacteria to be presented at ICAAC in Washington, DC, September 6th.**

Copenhagen, September 1 st 2014.

Adenium Biotech has been invited by the organizing committee of ICAAC 2014 to present its clinical product candidate AA139 during the "New Antimicrobial Agents" session during ICCAC, which is to take place in Washington DC from September 5 to 9<sup>th</sup>.

Adenium Biotech is a spin out from Novozymes. The company is focusing on the development of anti microbial peptides against multi- and pan drug-resistant Gram-negative and -positive bacteria. There is a desperate need for new anti infectives to combat the ever increasing challenge of multi- or pan drug resistant pathogens. Adenium's antimicrobial peptides are novel, possess a unique MoA, have a very low spontaneous frequency of mutation and are rapidly cidal.

AA139 with potent activity against the four major Gram-negative GAIN pathogens *E. coli*, *K. pneumonia*, *P. aeruginosa* and *A. baumannii* is Adenium's most advanced program and is expected to initiate First-in-man (FIM) studies in Q4 2015.

Dr Sergio Lociuero, Adenium's CSO, will present AA139 to the ICAAC congress during the plenum session on new anti infectives, accompanied by six posters that in more detail present AA139's mode of action, spectrum of activity and efficacy in a number of in vivo models.

Dr Peter Nordkild, CEO of Adenium: "This is the first time AA139 is presented to the scientific community and we are happy about the invitation to present AA139 at the New Antimicrobial Agents session of ICAAC 2014. We are in the process of finalizing the IND enabling studies and to initiate the preclinical tox/safety studies in February next year. If everything goes according to plan we should be able to initiate FIM clinical studies before the end of 2015.

For further information please contact:

Peter Nordkild, MD

CEO, Adenium Biotech

TLF: 00 45 25 47 16 46

E-mail: [pno@adeniumbiotech.com](mailto:pno@adeniumbiotech.com)

#### **About Adenium Biotech ApS.**

*Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium focuses on the development and commercialization of anti microbial peptides for the treatment of Gram-negative and -positive bacterial infections. Our focus is treatment of hospital acquired infections in particular complicated urinary tract infection and pneumonia caused by multi drug resistant Gram-negative bacteria as well as MRSA infections in patients with an osteo- or cardio implants. Adenium Biotech is managed by a small team of experts and supported by a very strong scientific advisory board.*